Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do I qualify for a cancer clinical trial?

2.

Short-course radiation matches standard therapy for endometrial cancer

3.

One-third of childhood cancer survivors experience significant fear that it could come back, study reveals

4.

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

5.

Eight Doctors Killed in Brazil's Horrifying Plane Crash


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot